Bioseeker, Sep 2007, Pages: 500
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive
FactSet, June 2008 R788 Lymphoma Phase 2 Results Call - Rigel Pharmaceuticals, Inc., - Earnings Transcript
Tuesday, June 03, 2008 12:00
Corrected Transcripts are verbatim transcripts that have been reviewed
FactSet, Aug 2007
Acquisition of Lymphoma Drug Zevalin(R) from Biogen Idec by Cell Therapeutics Inc Call - Cell Therapeutics, Inc., - Earnings Transcript
Thursday, August 16, 2007 12:30
Corrected Transcripts
Fore Pharma, Jan 2012, Pages: 13
Fore Pharma’s latest report ‘Global T Cell Lymphoma Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global T cell lymphoma drug
Fore Pharma, Aug 2011, Pages: 13
Fore Pharma’s latest report ‘Global T Cell Lymphoma Drug Pipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global T cell lymphoma drug
Bioseeker, May 2011, Pages: 954
This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181
The Assessment Group, April 2011, Pages: 61
Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma
Clinical Publishing, March 2010, Pages: 216
Gilson
28. Hodgkin lymphoma – advanced stage disease and long-term sequelae, D Gilson
29. High-grade diffuse large B-cell non-Hodgkin’s lymphoma, R Johnson
30. Primary central nervous system lymphoma, R
The Assessment Group, April 2011, Pages: 35
Figure 3.2 Confidence in treatment
Figure 3.3 First line treatment approach to patient with large cell lymphoma
Figure 3.4 Factors that influence treatment decision
Figure 3.5 Preferred R-CHOP regimen
Bioseeker, May 2011
"Analytical Tool: Lymphoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphomaR&D and business development. It is also a map
Bioseeker, June 2009, Pages: 535
This report includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total
Global Markets Direct, Dec 2010, Pages: 28
Lymphoma Study Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the German Low Grade Lymphoma Study Group’s R&D portfolio and develop key strategic initiatives
Global Markets Direct, Dec 2010, Pages: 28
and Newcastle Lymphoma Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Scotland and Newcastle Lymphoma Group’s R&D portfolio and develop key strategic initiatives
Datamonitor, Dec 2009, Pages: 187
The treatment outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients have improved since the introduction of Rituxan/MabThera (rituximab; Biogen Idec/Genentech
Global Markets Direct, Dec 2010, Pages: 45
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Indolent Lymphoma - Featured News
Dec 07, 2010: Celgene Presents Clinical Data From Two
Bioseeker, May 2011, Pages: 2923
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Colorectal Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized
Bioseeker, May 2011, Pages: 3014
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria
Bioseeker, July 2011, Pages: 3190
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria
